Kalbe Farma Distributes Dividends Of IDR 1.76 Trillion

JAKARTA - The pharmaceutical company PT Kalbe Farma Tbk (KLBF) at the Annual General Meeting of Shareholders (AGMS) in Jakarta, Wednesday, May 3, decided to distribute cash dividends of IDR 38 per share for the 2022 financial year.

Director of KLBF Bernadus Karmin said that the total dividend was IDR 1.76 trillion, or with a payout ratio of 52.5 percent of the company's net profit for the 2022 financial year of IDR 3.38 trillion.

"Use of profits, distribution of dividends totaling a value of IDR 1.76 trillion. Per share of IDR 38, or an increase (to) 52.5 percent pay out ratio," said Bernadus, quoted from Antara.

In accordance with the rules of the Financial Services Authority (OJK), he explained that cash dividends will be distributed no later than 30 days after the announcement of the results of the AGMS with a schedule and procedure to be announced immediately.

"Dividends will be distributed when to follow OJK rules, around three weeks or one month from today," said Bernadus

In the AGMS, the company also made changes to the composition of the management including adding Kartika Setiabudy as Director,

In addition, there was also Adi Harsono's resignation as Board of Commissioners, who was later replaced by Budi Dharma as Board of Commissioners.

On this occasion, Bernadus conveyed that the company in 2023 remains optimistic by projecting sales growth and net profit of 13 to 15 percent.

In addition, the company maintains a capital expenditure (capex) budget of IDR 1.0 trillion in 2023, which will be used to expand production and distribution capacity.

In the AGMS, the company approved and ratified the Company's Annual Report for the financial year ending on December 31, 2022, including the Company's Activity Report, the Supervisory Report of the Board of Commissioners and the Company's Financial Report for the financial year ending on December 31, 2022.

In addition, the payment and full release of responsibility to the Board of Commissioners and the Board of Directors of the Company for their supervisory and management actions in the financial year ending on December 31, 2022 (acquit et de charge).